Compare PDEX & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PDEX | DTIL |
|---|---|---|
| Founded | 1978 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.1M | 136.0M |
| IPO Year | 1995 | 2019 |
| Metric | PDEX | DTIL |
|---|---|---|
| Price | $51.67 | $5.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $56.00 | ★ $60.00 |
| AVG Volume (30 Days) | 20.7K | ★ 331.9K |
| Earning Date | 04-30-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 345.00 | N/A |
| EPS | ★ 2.07 | N/A |
| Revenue | $66,593,000.00 | ★ $1,070,000,000.00 |
| Revenue This Year | $7.22 | N/A |
| Revenue Next Year | N/A | $34.75 |
| P/E Ratio | $24.63 | ★ N/A |
| Revenue Growth | ★ 23.68 | N/A |
| 52 Week Low | $23.52 | $3.53 |
| 52 Week High | $70.26 | $8.82 |
| Indicator | PDEX | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 66.58 | 54.28 |
| Support Level | $37.15 | $3.96 |
| Resistance Level | $56.50 | $7.59 |
| Average True Range (ATR) | 2.94 | 0.58 |
| MACD | 0.04 | -0.15 |
| Stochastic Oscillator | 91.48 | 21.25 |
Pro-Dex Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers (OEMs) to various countries. Its product portfolio includes autoclavable, battery-powered, electric, and multi-function surgical drivers and shavers used mainly in orthopedic, thoracic, and craniomaxillofacial markets. The company also provides engineering, quality, regulatory consulting services, and manufactures rotary air motors utilized in various industries. Operating out of ISO-certified facilities in California, Pro-Dex serves hospitals, medical labs, and high-tech manufacturers, generating revenue through sales of surgical instruments and related services.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).